KLTO (Klotho Neurosciences) Total Stockholders Equity : $1.19 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Total Stockholders Equity?

Klotho Neurosciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.19 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Klotho Neurosciences's Book Value per Share for the quarter that ended in Dec. 2024 was $0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Klotho Neurosciences's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.23.

Klotho Neurosciences Total Stockholders Equity Historical Data

The historical data trend for Klotho Neurosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Total Stockholders Equity Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

1.03

1.18

0.57

1.19

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial					0.57	0.36	-1.55	1.46	1.19

Klotho Neurosciences (NAS:KLTO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Klotho Neurosciences's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1.185	-	0)	/	27.081
	=	0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Klotho Neurosciences's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.272	+	0)	/	1.185
	=	0.23

Klotho Neurosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, Suite A, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.